By Marilynn Larkin

NEW YORK (Reuters Health) – Adding evolocumab to statin therapy in high-risk patients with stable atherosclerotic heart disease may further reduce the risk of cardiovascular events, regardless of low-density lipoprotein (LDL) cholesterol level, researchers say.

READ MORE

News

By Marilynn Larkin

NEW YORK (Reuters Health) – Adding evolocumab to statin therapy in high-risk patients with stable atherosclerotic heart disease may further reduce the risk of cardiovascular events, regardless of low-density lipoprotein (LDL) cholesterol level, researchers say.

READ MORE

A real-life analysis compared multiple antidiabetic medications for increased risk of heart failure hospitalization.

READ MORE

Patients with asymptomatic severe aortic stenosis who do not adhere to guidelines for serial clinical evaluations are at a higher risk for all-cause mortality and heart failure hospitalization.

READ MORE

By Will Boggs MD

NEW YORK (Reuters Health) - Cardiovascular disease and mortality rates are lower in patients with type 2 diabetes who start taking sodium-glucose co-transporter-2 (SGLT2) inhibitors instead of other glucose-lowering drugs, according to results from the CVD-REAL Nordic study.

READ MORE